Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in α3-fucosylation of α1-acid glycoprotein

被引:31
作者
Havenaar, EC
Axford, JS
Brinkman-van der Linden, ECM
Alavi, A
Van Ommen, ECR
van het Hof, B
Spector, T
Mackiewicz, A
Van Dijk, W [1 ]
机构
[1] Vrije Univ Amsterdam, Dept Med Chem, NL-1081 BT Amsterdam, Netherlands
[2] St George Hosp, Sch Med, Dept Cellular & Mol Sci, Acad Rheumatol Unit, London SW17 0RE, England
[3] St Thomas Hosp, London, England
[4] Great Poland Canc Ctr, Med Acad, Dept Canc Immunol, PL-61866 Poznan, Poland
关键词
rheumatoid arthritis; Pregnancy; alpha; -acid glycoprotein; alpha(1)-anitchymotrypsin; alpha(1)-protease inhibitor; fucosylation;
D O I
10.1023/A:1006944700325
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Patients suffering from rheumatoid arthritis (RA) may experience a temporary reduction of disease symptoms during pregnancy. As indicated by the occurrence of RA-disease symptoms during pregnancy, three categories of patients were defined, namely, remission, relapse and unchanged. In all three categories changes in the plasma level and glycosylation of alpha(1)-acid glycoprotein (AGP) were determined longitudinally in comparison to those occurring in pregnancy of healthy women. In healthy pregnancy, we observed: (i) a peak in the plasma concentration at week 18 and a minimum at week 30; (ii) a continuous increase in the degree of branching of the glycans during the entire pregnancy period, and (iii) a decrease in the degree of alpha 3-fucosylation of AGP-glycans with a minimum occurring at week 25. Comparable pregnancy-induced changes in glycosylation were found for two other acute-phase proteins ai-protease inhibitor (PI) and alpha(1)-antichymotrypsin (ACT). Increased oestrogen levels, known to occur during pregnancy, may be one of the factors that induce these changes, because the increased branching and decreased alpha 3-fucosylation is in agreement with our earlier findings regarding an involvement of this hormone in the regulation of acute phase protein glycosylation in oestrogen-treated males as well as females. In all three clinical categories in RA, pregnancy also induced a continuous increase in the degree of branching of the glycans of AGP. However, similar changes in concentration and fucosylation were only found during remission of the disease symptoms. In the relapse and unchanged categories in RA, the degree of fucosylation and the plasma concentration of AGP remained constant throughout pregnancy. This indicates a relationship between changes in alpha 3-fucosylation of AGP and RA disease activity.
引用
收藏
页码:723 / 729
页数:7
相关论文
共 38 条
[11]   INHIBITION OF PLATELET-AGGREGATION BY NATIVE AND DESIALIZED ALPHA-1 ACID GLYCOPROTEIN [J].
COSTELLO, M ;
FIEDEL, BA ;
GEWURZ, H .
NATURE, 1979, 281 (5733) :677-678
[12]  
DARGAN E, 1994, GLYCOSYL DIS, V1, P37
[13]   INFLAMMATION-INDUCED EXPRESSION OF SIALYL LEWIS X-CONTAINING GLYCAN STRUCTURES ON ALPHA-1-ACID GLYCOPROTEIN (OROSOMUCOID) IN HUMAN SERA [J].
DEGRAAF, TW ;
VANDERSTELT, ME ;
ANBERGEN, MG ;
VANDIJK, W .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (03) :657-666
[14]  
DEGRAAF TW, 1994, J RHEUMATOL, V21, P2209
[15]   IMMUNOLOGICAL RESPONSES IN PREGNANCY AND SURVIVAL OF FETAL HOMOGRAFT [J].
FINN, R ;
HILL, CAS ;
RALFS, IG ;
DENYE, V ;
GOVAN, AJ ;
GURNEY, FJ .
BRITISH MEDICAL JOURNAL, 1972, 3 (5819) :150-&
[16]   DETERMINATION OF PRIMARY STRUCTURES OF 16 ASIALO-CARBOHYDRATE UNITS DERIVED FROM HUMAN-PLASMA ALPHA-1-ACID GLYCOPROTEIN BY 360-MHZ H-1 NMR-SPECTROSCOPY AND PERMETHYLATION ANALYSIS [J].
FOURNET, B ;
MONTREUIL, J ;
STRECKER, G ;
DORLAND, L ;
HAVERKAMP, J ;
VLIEGENTHART, JFG ;
BINETTE, JP ;
SCHMID, K .
BIOCHEMISTRY, 1978, 17 (24) :5206-5214
[17]  
FOX HS, 1991, J IMMUNOL, V146, P4362
[18]  
Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127
[19]   Do synovial fluid acute phase proteins from patients with rheumatoid arthritis originate from serum? [J].
Havenaar, EC ;
Dolhain, RJEM ;
Turner, GA ;
Goodarzi, MT ;
vanOmmen, ECR ;
Breedveld, FC ;
vanDijk, W .
GLYCOCONJUGATE JOURNAL, 1997, 14 (04) :457-465
[20]  
HU SK, 1988, INT J IMMUNOPHARMACO, V10, P247